NEW YORK, April 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK),
Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation
(NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private
wealth members receive these notes ahead of publication. To reserve
complementary membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Pfizer Inc. Analyst Notes
On April 6, 2014, Pfizer Inc.
(Pfizer) released detailed results from the PALOMA-1 study.
According to the release, PALOMA-1, a randomized Phase 2 study of
palbociclib (PD-0332991) in combination with letrozole, has
achieved its primary endpoint by significantly extending
progression-free survival (PFS) compared with letrozole alone in
postmenopausal women with estrogen receptor positive (ER+), human
epidermal growth factor receptor 2 negative (HER2-) locally
advanced or metastatic breast cancer. Pfizer stated that for women
who were treated with the combination of palbociclib plus
letrozole, the median PFS was 20.2 months, a statistically
significant improvement compared to the 10.2 months of PFS in women
who received letrozole alone (HR=0.488 [95% CI: 0.319, 0.748];
p=0.0004). Dr. Mace Rothenberg, Senior Vice President of Clinical
Development and Medical Affairs and Chief Medical Officer for
Pfizer Oncology, stated, "These data demonstrate the potential of
palbociclib to be a major advance in the treatment of women with
this type of advanced breast cancer. We are proud to be at the
forefront of research and development with respect to this
promising new class of investigational anticancer agents and have
initiated a broad clinical development program for palbociclib that
includes breast and non-breast cancers." The full analyst notes on
Pfizer Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/PFE/report.pdf
--
Cytokinetics, Incorporated Analyst Notes
On March 28, 2014, Cytokinetics,
Incorporated (Cytokinetics) announced that the COSMIC-HF (Chronic
Oral Study of Myosin Activation to Increase Contractility in Heart
Failure) expansion phase, has opened for enrollment. Cytokinetics
stated that COSMIC-HF is a Phase II double-blind, randomized,
placebo-controlled, multicenter clinical trial designed to assess
the pharmacokinetics and tolerability of omecamtiv mecarbil dosing
orally in patients with heart failure and left ventricular systolic
dysfunction. According to the Company, the COSMIC-HF expansion
phase will enroll approximately 450 patients randomized 1:1:1 to
receive placebo, 25 mg, or 50 mg twice daily of omecamtiv mecarbil,
with an escalation to the 50 mg dose depending on the plasma
concentration of omecamtiv mecarbil following 2 weeks of oral
dosing at 25 mg twice daily. Cytokinetics' Senior Vice President of
Clinical Research and Development and Chief Medical Officer,
Andrew A. Wolff, M.D., FACC, stated,
"The opening to enrollment of the expansion phase of COSMIC-HF is
an important step forward in the evaluation of a plasma
concentration-guided dose titration strategy for omecamtiv mecarbil
in patients with heart failure. This international clinical trial
has the potential to inform further clinical development strategies
for omecamtiv mecarbil." The full analyst notes on Cytokinetics,
Incorporated are available to download free of charge at:
http://www.AnalystsReview.com/04092014/CYTK/report.pdf
--
Portola Pharmaceuticals, Inc. Analyst Notes
On March 27, 2014, Portola
Pharmaceuticals, Inc. (Portola Pharmaceuticals) announced that it
has initiated a Phase 2 proof-of-concept study to evaluate
andexanet alfa, the potential First-in-Class Factor Xa Inhibitor
Reversal Agent as a reversal agent for Daiichi Sankyo's oral,
once-daily, direct Factor Xa inhibitor edoxaban in healthy
volunteers. According to the release, the Company is pursuing an
Accelerated Approval pathway for andexanet alfa, the only agent
that has demonstrated reversal of the anticoagulation activity of
Factor Xa inhibitors treated patients who are suffering a major
bleeding episode or who require emergency surgery. John T. Curnutte, M.D., Ph.D., Executive Vice
President, Research and Development at the Company, stated, "Our
development team leveraged our cutting-edge science in the area of
thrombosis to create andexanet alfa as a possible solution. The
initiation of this new Phase 2 study with edoxaban moves us closer
to our goal of bringing andexanet alfa to market as a universal
antidote for Factor Xa inhibitors." According to the Company, in
the said clinical collaboration between Portla Phamaceuticals and
Daiichi Sankyo for the Phase 2 study Daiichi Sankyo provides
funding for the study while Portola retains full worldwide
commercial rights to andexanet alfa. The full analyst notes on
Portola Pharmaceuticals, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04092014/PTLA/report.pdf
--
Volcano Corporation Analyst Notes
On April 4, 2014, Volcano
Corporation's (Volcano) stock dipped by 3.76%, closing the day at
$19.73 per share. However, for the
past five day trading period, the Volcano shares increased by 2.07%
compared to the Nasdaq Composite which declined by 0.67% during the
same period. The full analyst notes on Volcano Corporation are
available to download free of charge at:
http://www.AnalystsReview.com/04092014/VOLC/report.pdf
--
Array BioPharma, Inc. Analyst Notes
On April 4, 2014, Array BioPharma,
Inc.'s (Array BioPharma) shares slipped by 5.01%, closing at
$4.17 per share. Over the previous
six month trading session, Array BioPharma stock price reflected a
decrease of 35.75%, compared to the Nasdaq Composite which
increased by 8.40% during the same trading period. The full analyst
notes on Array BioPharma, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04092014/ARRY/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review